Investigating the German response scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) – a three-step approach

Investigating the German response scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) – a three-step approach - EORTC Response Scale

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012759

Enrollment

500

Registered

2017-08-04

Start date

2016-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adaption of the German version of the questionnaire for cancer patients EORTC QLQ-C30

Interventions

Group 1: Step I investigates the properties of the critical response term “mäßig” and its alternatives. Group 2: Step II refers to the development of an updated German EORTC QLQ-C30 version with an i

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Cancer, informed consent, ability to fill in a questionnaire

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the score of the EORTC QLQ-C30 as calculated according to the scoring manual. The score will be calculated twice, with regard to the the first and the second assessment. The critical value of interest is the difference between scores of the conventional and the updated version. This difference will be assessed in the between (group comparisons) and within (before-after effects) conditions.	—

Measure

Time frame

The primary endpoint is the score of the EORTC QLQ-C30 as calculated according to the scoring manual. The score will be calculated twice, with regard to the the first and the second assessment. The critical value of interest is the difference between scores of the conventional and the updated version. This difference will be assessed in the between (group comparisons) and within (before-after effects) conditions.

—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactMichael Koller

Universitätsklinikum RegensburgZentrum für Klinische Studien

michael.koller@ukr.de0941 944 5630

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 21, 2026